Static list review decision – August 2017
Static list review
As you may be aware TA178; Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma.
Guidance is moved to the static list following consultation with consultees and commentators when it is clear that there is no new research available that would have any material effect on the current guidance. Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
As the appraisal has been on the static list for more than 5 years, NICE has been gathering intelligence to ascertain whether there is any new evidence available relevant to this appraisal and whether this should be considered through the full review proposal process.
No new evidence has been identified that would lead to a change in the existing recommendations.
As a result, we are contacting stakeholders who were involved in the last review proposal for this appraisal to inform them that we have decided that TA178 should remain on the static list and no further action is required at this time.
However, if NICE is notified of a significant change to the evidence base at any stage in the future, this could trigger a formal review proposal.
This page was last updated: